Lupin In Pact With SteinCares To Supply Biosimilar Ranibizumab In Latin America

Lupin Ltd on Monday announced a partnership with specialty healthcare firm SteinCares to supply its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina. Under the deal, Lupin will manufacture ranibizumab, while SteinCares will manage all regulatory filings, registrations, and commercialisation in the region.

Ranibizumab is used to treat conditions such as neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularisation.